NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I only believe there is one reason not to unblind, that being they've not yet completely settled on an SAP that all 4 regulators agree on. Beyond that, any other reason has little, or no validity.

Of course it's very possible it's been agreed to and as we spend time speculating they're gathering information from all clinical sites. They could easily be hung up by just a few patients believed to still be alive that they're attempting to track down. In an interim look, calling a patient LTFU is no big thing, but when gathering up the final data, I believe they do not wish to have anyone in that catagory, even if they 5 years or more into the trial.

We're now at the point where even the last patient to enter the trial if currently alive would be near 4.5 years since beginning the trial, by far most of the living are beyond 5 years, and many probably beyond 6 or 7 years. I don't know how many are alive, but with the SOC it would probably be less than 15, so I believe we'll demonstrate a tremendous improvement on the SOC. Have improvements been made over the years in the trial that effect what the SOC is, we know they have surgically, and some of the later entrants in the trial may have benefitted from this as well, but still the benefits of the drug should be clear.

Gary